ABERRANT EXPRESSION OF THE C-ERBB-2/NEU PROTOONCOGENE IN OVARIAN-CANCER

被引:91
|
作者
HUNG, MC [1 ]
ZHANG, X [1 ]
YAN, DH [1 ]
ZHANG, HZ [1 ]
HE, GP [1 ]
ZHANG, TQ [1 ]
SHI, DR [1 ]
机构
[1] SHANGHAI MED UNIV, HOSP CANC, INST CANC, DEPT PATHOL, SHANGHAI 20032, PEOPLES R CHINA
关键词
HER-2; C-ERB-2/NEU; ONCOGENE; OVARIAN CANCER;
D O I
10.1016/0304-3835(92)90166-S
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Overexpression of the c-erbB-2/neu protooncogene has recently been shown in ovarian tumors collected from the United States. It is known that environmental and cultural factors may contribute to certain types of cancer, therefore, we examined expression of c-erbB-2/neu in ovarian tumors collected from China by immunohistochemical staining. Out of 81 tumor specimens, 57 (70.4%) were found to be immunopositive, whereas only one out of 17 (5.9%) normal ovarian tissue samples was slightly positive. Our results indicate that overexpression of c-erbB-2/neu is a general phenomenon for ovarian cancer regardless of different population. To search for a c-erbB/neu overexpressing cell line for future study on molecular mechanism, we also analyzed 13 cancer cell lines from the female genital tract for expression of c-erbB-2/neu. The c-erbB-2/neu RNA was found to be overexpressed at least 100-fold in one of the four ovarian cancer cell lines examined. An aberrant c-erbB-2/neu RNA was also found to be overexpressed in this cell line. Southern blot analysis indicated that the c-erbB-2/neu was amplified 2 - 4-fold in this line, and some of these alleles have structural alteration which may account for expression of the aberrant c-erbB-2/neu RNA. Since the 2 - 4-fold gene amplification is not proportional to the > 100-fold overexpression in RNA, other mechanisms such as transcriptional or post-transcriptional control must be involved in overexpression of this gene in ovarian cancer.
引用
收藏
页码:95 / 103
页数:9
相关论文
共 50 条
  • [11] HER-2/neu (c-erbB-2) Expression Assessment in Breast Cancer
    Ioanid, N.
    Anton, E.
    Socolov, Demetra
    GINECO RO, 2009, 5 (01): : 43 - 47
  • [12] THE NEU (C-ERBB-2) ONCOGENE
    MAGUIRE, HC
    GREENE, MI
    SEMINARS IN ONCOLOGY, 1989, 16 (02) : 148 - 155
  • [13] EXPRESSION OF C-ERBB-2 (NEU) IN HUMAN-SKIN
    MAGUIRE, HC
    JAWORSKY, C
    COHEN, JA
    WEINER, DB
    HELLMAN, ME
    GREENE, MI
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1989, 92 (03) : 474 - 474
  • [14] EXPRESSION OF C-ERBB-2 (NEU) IN HUMAN-SKIN
    MAGUIRE, HC
    JAWORSKY, C
    COHEN, JA
    WEINER, DB
    HELLMAN, ME
    GREENE, MI
    CLINICAL RESEARCH, 1989, 37 (02): : A758 - A758
  • [15] IMMUNOHISTOCHEMICAL STAINING OF THE C-ERBB-2 (NEU) PROTOONCOGENE PRODUCT IN HUMAN BREAST-TISSUE
    BARNES, DM
    LAMMIE, GA
    MILLIS, RR
    MASTOLOGY 88, 1988, 792 : 351 - 356
  • [16] EXPRESSION OF THE HER-2/NEU/C-ERBB-2 ONCOGENE IN BREAST-CANCER
    PRESS, MF
    GODOLPHIN, W
    SLAMON, DJ
    LABORATORY INVESTIGATION, 1989, 60 (01) : A73 - A73
  • [17] ELEVATED SERUM LEVELS OF A C-ERBB-2 ONCOGENE PRODUCT IN OVARIAN-CANCER PATIENTS AND IN PREGNANCY
    MEDEN, H
    MARX, D
    FATTAHI, A
    RATH, W
    KRON, M
    WUTTKE, W
    SCHAUER, A
    KUHN, W
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 1994, 120 (06) : 378 - 381
  • [18] OVEREXPRESSION OF C-ERBB-2 IN EPITHELIAL OVARIAN-CANCER - PROGNOSTIC VALUE AND RELATIONSHIP WITH RESPONSE TO CHEMOTHERAPY
    FELIP, E
    DELCAMPO, JM
    RUBIO, D
    VIDAL, MT
    COLOMER, R
    BERMEJO, B
    CANCER, 1995, 75 (08) : 2147 - 2152
  • [19] EXPRESSION OF NEU/C-ERBB-2 IN HUMAN BRAIN-TUMORS
    SCHWECHHEIMER, K
    LAUFLE, RM
    SCHMAHL, W
    KNODLSEDER, M
    FISCHER, H
    HOFLER, H
    HUMAN PATHOLOGY, 1994, 25 (08) : 772 - 780
  • [20] GAMMA-INTERFERON REDUCES EXPRESSION OF THE PROTOONCOGENE C-ERBB-2 IN HUMAN OVARIAN-CARCINOMA CELLS
    MARTH, C
    MULLERHOLZNER, E
    GREITER, E
    CRONAUER, MV
    ZEIMET, AG
    DOPPLER, W
    EIBL, B
    HYNES, NE
    DAXENBICHLER, G
    CANCER RESEARCH, 1990, 50 (21) : 7037 - 7041